Read on Twitter
Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors
#COVID19
Detection of SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cells in peripheral blood.
Presence of S-reactive CD4+ T cells in 83% of COVID-19 patients, as well as in 34% of
#COVID19
Detection of SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cells in peripheral blood.
Presence of S-reactive CD4+ T cells in 83% of COVID-19 patients, as well as in 34% of
SARS-CoV-2 seronegative healthy donors, albeit at lower frequencies demonstrated.
in COVID-19 patients S-reactive CD4+ T cells equally targeted both N-terminal and C-terminal parts of S whereas in healthy donors S-reactive CD4+ T cells reacted almost exclusively to the C terminus
in COVID-19 patients S-reactive CD4+ T cells equally targeted both N-terminal and C-terminal parts of S whereas in healthy donors S-reactive CD4+ T cells reacted almost exclusively to the C terminus
part that is a) characterized by higher homology to spike glycoprotein of human endemic "common cold" coronaviruses, and b) contains the S2 subunit of S with the cytoplasmic peptide (CP), the fusion peptide (FP), and the transmembrane domain (TM).
but not the receptor-binding domain (RBD). ). S-reactive CD4+ T cells from COVID-19 patients were further distinct to those from healthy donors as they co-expressed higher levels of CD38 and HLA-DR, indicating their recent in vivo activation.
Larger scale prospective cohort studies will be needed to see whether their presence is a correlate of protection or pathology.
Presence of #COVID19 reactive T-cells is significant to understand whether they cause illness or provide protection.
Presence of #COVID19 reactive T-cells is significant to understand whether they cause illness or provide protection.
